ProKidney Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROK research report →
About the company
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells.
- CEO
- Bruce Culleton
- IPO
- 2021
- Employees
- 204
- HQ
- Winston-Salem, NC, US
Price Chart
- Market Cap
- $682.60M
- P/E
- -3.69
- P/S
- 1742.52
- P/B
- -0.28
- EV/EBITDA
- -9.65
- Div Yield
- 0.00%
- Gross Margin
- -224.41%
- Op Margin
- -18959.73%
- Net Margin
- -8418.00%
- ROE
- 7.40%
- ROIC
- -54.77%
- Revenue
- $893.00K · 1075.00%
- Net Income
- $-68,986,000 · -12.75%
- EPS
- $-0.52 · 16.13%
- Op Income
- $-165,007,000
- FCF YoY
- 13.18%
- 52W High
- $7.13
- 52W Low
- $0.59
- 50D MA
- $1.80
- 200D MA
- $2.22
- Beta
- 1.70
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on PROK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | Girolamo Todd C | other | 163,857 |
| Jun 12, 26 | Girolamo Todd C | other | 163,857 |
| Jun 12, 26 | Girolamo Todd C | other | 163,857 |
| Jun 1, 26 | Locke Kenneth Thomas | other | 0 |
| May 28, 26 | Lotvin Alan | other | 135,000 |
| May 28, 26 | Jimenez Santos Jose Ignacio | other | 135,000 |
| May 28, 26 | Fox Jennifer A. | other | 135,000 |
| May 28, 26 | DOYLE WILLIAM F | other | 135,000 |
| May 28, 26 | Sinha Uma | other | 135,000 |
| May 28, 26 | Legorreta Pablo G. | other | 135,000 |
Our PROK coverage
Recent articles, reports, and earnings notes.
No research on PROK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PROK report →Similar companies
Peers in the same neighborhood.